In addition, the administration of anti-G9a drugs confirmed this response in hepatocellular carcinoma [48] and in cervical cancer [43] via BIX01294, or in breast cancer via UNC0642 [49]. This evidence concerns the gene EHMT2 and hepatocellular carcinoma.